Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Big Pharma Push Back On First Medicare Drug Price Cuts

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

International Business Times

Big Pharma fought to keep prices high

Big Pharma exploited patent laws to stifle competition amid Medicare price negotiations, according to a new report

Salon

Reeves should nail down UK AstraZeneca deal. A collapse would be embarrassing

Chancellor hopes to cut state aid for Speke vaccine plant to £40m. But pro-growth Treasury must not let project slip overseas

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Blow to AstraZeneca vaccine project as Reeves plans funding cuts

Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant

The Guardian - UK

BranchLab Adds Errol Taylor as Advisor with Additional States Making Pharma Marketing More Difficult

Startup says it can provide consumer privacy and campaign effectiveness

Broadcasting & Cable

FTSE 100 chief executive pay reaches highest level on record

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

The Guardian - UK

‘Mind-boggling’: Victorian outreach workers decry double standard for lifesaving overdose drug naloxone

Untrained bystanders can legally administer the opioid-reversal treatment – but frontline staff workers face a legal risk if they do not first call triple zero

The Guardian - AU

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.

Kiplinger

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

StockNews.com

Drugstores tinker with new looks as their usual way of doing business faces challenges

America’s drugstores are testing smaller locations and more ways to offer care as more store closings loom

The Independent UK

GSK’s health is improving. Shame about the legal heartburn

Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed

The Guardian - UK

Pfizer Stock Slips After Beat-And-Raise Quarter: What to Know

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

Kiplinger

Reckitt Benckiser’s shares slump after Abbott baby formula ruling over bowel disease link

British group says claims products cause serious bowel condition NEC are ‘not supported by science’

The Guardian - UK

'Grinding halt': shortage could cause hospital chaos

Australia's health system could come to a "grinding halt" within days if a shortage of intravenous fluid isn't addressed, a leading doctor has warned.

AAP

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Bosses Resign At Japan Health Supplement Firm Probing Deaths

The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes dozens of deaths potentially linked to products meant to lower cholesterol.

The Conversation

Dear Pharmac – do things differently: what David Seymour’s expectations could mean for the drug-buying agency

Associate Health Minister David Seymour’s recent letter of expectations to drug buying agency Pharmac could fundamentally change the way the organisation makes decisions. Some of these changes could also make Pharmac’s job harder and its decisions more unpopular.

The Guardian - US

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

International Business Times

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Healthcare Stocks With High Profit Margins

With an aging population, increasing drug demand, and the development of advanced technologies, the healthcare industry is booming. Thus, it could be wise to invest in fundamentally sound healthcare stocks, Veeva Systems (VEEV), Align Technology (ALGN), and Medpace Holdings (MEDP), which have high-profit margins. Read on.

StockNews.com

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

Caixin Global

Shanghai Composite Index Ended Nearly Flat on Friday

Shenzhen Component Index closed down 0.18%

The Independent UK

The threat of litigation looms as Purdue Pharma returns to settlement talks

OxyContin maker Purdue Pharma, the family that owns it and lawyers for thousands of parties with claims against it are getting ready to work on a new settlement after the U.S. Supreme Court rejected the last one

The Independent UK

South Africa drops probe of J&J after it agrees to lower price of TB drug and withdraws patent

Medical advocacy groups welcomed Johnson & Johnson’s decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices, after South African authorities opened an investigation into the conglomerate

Evening Standard

London biotech secures £90 million backing

Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers

StockNews.com

3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

1 … 30 31 32 33

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.